These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19380597)

  • 1. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates.
    Weisman LE; Thackray HM; Garcia-Prats JA; Nesin M; Schneider JH; Fretz J; Kokai-Kun JF; Mond JJ; Kramer WG; Fischer GW
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2879-86. PubMed ID: 19380597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis.
    Weisman LE; Thackray HM; Steinhorn RH; Walsh WF; Lassiter HA; Dhanireddy R; Brozanski BS; Palmer KG; Trautman MS; Escobedo M; Meissner HC; Sasidharan P; Fretz J; Kokai-Kun JF; Kramer WG; Fischer GW; Mond JJ
    Pediatrics; 2011 Aug; 128(2):271-9. PubMed ID: 21788224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants.
    Patel M; Kaufman DA
    Expert Opin Biol Ther; 2015 Apr; 15(4):595-600. PubMed ID: 25736524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antistaphylococcal immunoglobulins to prevent staphylococcal infection in very low birth weight infants.
    Shah PS; Kaufman DA
    Cochrane Database Syst Rev; 2009 Apr; (2):CD006449. PubMed ID: 19370635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults.
    Weisman LE; Fischer GW; Thackray HM; Johnson KE; Schuman RF; Mandy GT; Stratton BE; Adams KM; Kramer WG; Mond JJ
    Int Immunopharmacol; 2009 May; 9(5):639-44. PubMed ID: 19268719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody for the prevention of neonatal noscocomial staphylococcal infection: a review of the literature.
    Weisman LE
    Arch Pediatr; 2007 Sep; 14 Suppl 1():S31-4. PubMed ID: 17939955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants.
    DeJonge M; Burchfield D; Bloom B; Duenas M; Walker W; Polak M; Jung E; Millard D; Schelonka R; Eyal F; Morris A; Kapik B; Roberson D; Kesler K; Patti J; Hetherington S
    J Pediatr; 2007 Sep; 151(3):260-5, 265.e1. PubMed ID: 17719934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants.
    Bloom B; Schelonka R; Kueser T; Walker W; Jung E; Kaufman D; Kesler K; Roberson D; Patti J; Hetherington S;
    Pediatr Infect Dis J; 2005 Oct; 24(10):858-66. PubMed ID: 16220082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting
    Magyarics Z; Leslie F; Bartko J; Rouha H; Luperchio S; Schörgenhofer C; Schwameis M; Derhaschnig U; Lagler H; Stiebellehner L; Firbas C; Weber S; Campanaro E; Jilma B; Nagy E; Stevens C
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selenium Supplementation for Prevention of Late-Onset Sepsis in Very Low Birth Weight Preterm Neonates.
    Aggarwal R; Gathwala G; Yadav S; Kumar P
    J Trop Pediatr; 2016 Jun; 62(3):185-93. PubMed ID: 26867560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
    Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin.
    Benjamin DK; Schelonka R; White R; Holley HP; Bifano E; Cummings J; Adcock K; Kaufman D; Puppala B; Riedel P; Hall B; White J; Cotton CM;
    J Perinatol; 2006 May; 26(5):290-5. PubMed ID: 16598296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D.
    Hawthorne T; Giot L; Blake L; Kuang B; Gerwien R; Smithson G; Hahne W; Mansfield T; Starling GC; Pochart P; Hoelscher D; Halvorsen YD
    Int J Clin Pharmacol Ther; 2008 May; 46(5):236-44. PubMed ID: 18538109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults.
    Yu XQ; Robbie GJ; Wu Y; Esser MT; Jensen K; Schwartz HI; Bellamy T; Hernandez-Illas M; Jafri HS
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study.
    Playford EG; Munro T; Mahler SM; Elliott S; Gerometta M; Hoger KL; Jones ML; Griffin P; Lynch KD; Carroll H; El Saadi D; Gilmour ME; Hughes B; Hughes K; Huang E; de Bakker C; Klein R; Scher MG; Smith IL; Wang LF; Lambert SB; Dimitrov DS; Gray PP; Broder CC
    Lancet Infect Dis; 2020 Apr; 20(4):445-454. PubMed ID: 32027842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.
    Sivapalasingam S; Kamal M; Slim R; Hosain R; Shao W; Stoltz R; Yen J; Pologe LG; Cao Y; Partridge M; Sumner G; Lipsich L
    Lancet Infect Dis; 2018 Aug; 18(8):884-893. PubMed ID: 29929783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults.
    Ishida JH; Burgess T; Derby MA; Brown PA; Maia M; Deng R; Emu B; Feierbach B; Fouts AE; Liao XC; Tavel JA
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4919-29. PubMed ID: 26055360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth, efficacy, and safety of feeding an iron-fortified human milk fortifier.
    Berseth CL; Van Aerde JE; Gross S; Stolz SI; Harris CL; Hansen JW
    Pediatrics; 2004 Dec; 114(6):e699-706. PubMed ID: 15545616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers.
    Allison DE; Gourlay SG; Koren E; Miller RM; Fox JA
    BioDrugs; 2002; 16(1):63-70. PubMed ID: 11968154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.